New Two-Drug attack on Tough-to-Treat hodgkin lymphoma
Disease control
Recruiting now
This study is testing a combination of two drugs, nivolumab and ruxolitinib, for adults whose Hodgkin lymphoma has returned or not responded to prior treatments. The first part aims to find the safest dose of ruxolitinib to give with nivolumab. The second part will see how well t…
Phase: PHASE1, PHASE2 • Sponsor: Veronika Bachanova • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC